NCT02454010: A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: CDH3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients with tumors that express CDH3 are eligible for the expansion phase
Exclusions: Patients with unstable untreated brain metastases- see trial for details; Patients with known autoimmune disease

Comments are closed.

Up ↑